Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in North America:
Eisai Company Limited
sales of $5.79 billion
of which 88%
was Pharmaceutical Business),
of which 51%
was US), and
Alexion Pharmaceuticals, Inc.
of which 80%
Grifols SA reported sales of $5.70 billion
December of 2019.
increase of 7.8%
versus 2018, when the company's sales were $5.29 billion.
This was the fourth straight year of sales growth at Grifols SA.
Sales of Bio Supplies saw an increase
that was more than double the company's growth rate: sales were up
51.4% in 2019, from
$196.77 million to $297.93 million.
Not all segments of Grifols SA experienced an increase in sales in 2019:
sales of Others/raw Materials fell 3.6% to $25.51 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Grifols SA also experienced decreases in sales in
Diagnostics (down 0.9% to $819.99 million)